# US 2026/0062485 A1 · Antigen binding molecules

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0062485 A1
- Document ID: US20260062485A1
- Status: Published application
- Kind: A1
- Application number: 19/208,349
- Filed: 2025-05-14
- Published: 2026-03-05
- Earliest claimed: 2022-11-15
- Assignees: Hoffmann-La Roche Inc.
- Applicants: Hoffmann-La Roche Inc.
- Inventors: Jamal Abu Tarbush; Ali Bransi; John Challier; Sofia Helena Linnea Frost; Guy Georges; Friederike Hesse; Sabine Imhof-Jung; Christian Klein; Laurent Lariviere
- Web page: https://patentgrep.com/patent/US20260062485A1

## CPC

- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- A61P 35/00: Antineoplastic agents
- C07K 16/32: against translation products of oncogenes
- A61K 2039/505: {comprising antibodies}
- C07K 2317/31: multispecific
- C07K 2317/35: Valency
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/526: CH3 domain
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/64: comprising a combination of variable region and constant region components
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to a pair of binding molecules comprising complementary parts of an effector domain, such binding molecules being capable of forming a functional effector domain when bound to their target antigens on the surface of a cell. Specifically, the invention relates to a pair of binding molecules wherein the complementary parts of the effector domain are complemented with inert complementing domains while the functional effector domain is not formed, providing advantageous properties, such as produceability, stability and/or biological functionality, to the binding molecules.

## Claims

### Claim 1

A pair of binding molecules, comprising
(a) a first binding molecule comprising (i) a first antigen binding domain capable of binding to a target antigen, (ii) a first part of an effector domain, and (iii) a first complementing domain capable of association with the first part of the effector domain; and
(b) a second binding molecule comprising (i) a second antigen binding domain capable of binding to a target antigen, (ii) a second part of an effector domain, and (iii) a second complementing domain capable of association with the second part of the effector domain;
wherein the first and the second part of the effector domain are capable of associating with each other to form a functional effector domain if the first and the second antigen binding domain bind to their target antigens on the surface of a cell,
wherein the first and the second complementing domain are associated with the first and the second part of the effector domain, respectively, while the first and the second part of the effector domain are not associated with each other; and
wherein the first and the second complementing domain are not capable of forming a functional effector domain with a part of the effector domain.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The pair of binding molecules of claim 1, wherein the effector domain is an anti-CD3 antigen binding domain.

### Claim at position 4

-6. (canceled)

### Claim 7 (depends on 1)

The pair of binding molecules of claim 1, wherein the first part of the effector domain comprises a heavy chain variable region (VH) and the second part of the effector domain comprises a light chain variable region (VL).

### Claim 8 (depends on 7)

The pair of binding molecules of claim 7, wherein
(a) the VH comprises a heavy chain complementarity determining region (HCDR) 1 of SEQ ID NO: 15, the HCDR 2 of SEQ ID NO: 16 and the HCDR 3 of SEQ ID NO: 17, and the VL comprises a light chain complementarity determining region (LCDR) 1 of SEQ ID NO: 19, a LCDR 2 of SEQ ID NO: 20 and a LCDR 3 of SEQ ID NO: 21; or
(b) the VH comprises a heavy chain complementarity determining region (HCDR) 1 of SEQ ID NO: 23, the HCDR 2 of SEQ ID NO: 24 and the HCDR 3 of SEQ ID NO: 25, and the VL comprises a light chain complementarity determining region (LCDR) 1 of SEQ ID NO: 27, a LCDR 2 of SEQ ID NO: 28 and a LCDR 3 of SEQ ID NO: 29; or
(c) the VH comprises a heavy chain complementarity determining region (HCDR) 1 of SEQ ID NO: 31, the HCDR 2 of SEQ ID NO: 32 and the HCDR 3 of SEQ ID NO: 33, and the VL comprises a light chain complementarity determining region (LCDR) 1 of SEQ ID NO: 35, a LCDR 2 of SEQ ID NO: 36 and a LCDR 3 of SEQ ID NO: 37; or
(d) the VH comprises a heavy chain complementarity determining region (HCDR) 1 of SEQ ID NO: 23, the HCDR 2 of SEQ ID NO: 24 and the HCDR 3 of SEQ ID NO: 60, and the VL comprises a light chain complementarity determining region (LCDR) 1 of SEQ ID NO: 27, a LCDR 2 of SEQ ID NO: 28 and a LCDR 3 of SEQ ID NO: 29.

### Claim 9 (depends on 8)

The pair of binding molecules of claim 8, wherein
(a) the VH comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 18, and/or the VL comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 22; or
(b) the VH comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 26, and/or the VL comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 30; or
(c) the VH comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 34, and/or the VL comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 38; or
(d) the VH comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 61, and/or the VL comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 30.

### Claim at position 8

-16. (canceled)

### Claim 17 (depends on 1)

The pair of binding molecules of claim 1, wherein the first complementing domain comprises a VL and the second complementing domain comprises a VH, wherein the VH and the VL are non-antigen binding.

### Claim 18

(canceled)

### Claim 19 (depends on 17)

The pair of binding molecules of claim 17, wherein the VH comprises a heavy chain complementarity determining region (HCDR) 1 of SEQ ID NO: 47, the HCDR 2 of SEQ ID NO: 48 and the HCDR 3 of SEQ ID NO: 49, and the VL comprises a light chain complementarity determining region (LCDR) 1 of SEQ ID NO: 51, a LCDR 2 of SEQ ID NO: 52 and a LCDR 3 of SEQ ID NO: 53.

### Claim 20

(canceled)

### Claim 21 (depends on 1)

The pair of binding molecules of claim 1, wherein the first part of the effector domain comprises a first VH and the first complementing domain comprises a first VL, and the second part of the effector domain comprises a second VL and the second complementing domain comprises a second VH.

### Claim 22 (depends on 21)

The pair of binding molecules of claim 21, wherein each of the second VH and the first VL and/or each of the first VH and the second VL comprise an amino acid substitution wherein an amino acid residue is substituted for a charged replacement amino acid residue, wherein (i) the replacement amino acid residues in the VH and the VL are of opposite charge, or (ii) the replacement amino acid residues in the VH and the VL are of the same charge.

### Claim 23 (depends on 1)

The pair of binding molecules of claim 1, wherein the first binding molecule comprises a third antigen binding domain capable of binding to a target antigen, and/or the second binding molecule comprises a fourth antigen binding domain capable of binding to a target antigen.

### Claim at position 16

-34. (canceled)

### Claim 35 (depends on 1)

The pair of binding molecules of claim 1, wherein the first binding molecule comprises a first Fc domain composed of a first and a second subunit, and/or the second binding molecule comprises a second Fc domain composed of a first and a second subunit.

### Claim 36

(canceled)

### Claim 37 (depends on 35)

The pair of binding molecules of claim 35, wherein
the Fc domain is a human Fc domain;
the Fc domain is a human IgG Fc domain;
the Fc domain comprises a modification promoting the association of the first and the second subunit of the Fc domain; and/or
the Fc domain comprises one or more amino acid substitution that reduces binding to an Fc receptor and/or effector function.

### Claim at position 20

-40. (canceled)

### Claim 41 (depends on 1)

The pair of binding molecule of claim 1, wherein
the first binding molecule comprises (i) a first and optionally a third antigen binding domain, (ii) an Fc domain composed of a first and a second subunit, (iii) a first part of an effector domain, and (iv) a first complementing domain,
wherein
(a) the first and the third (where present) antigen binding domain is fused at its C-terminus to the N-terminus of one of the subunits of the Fc domain,
(b) the first part of the effector domain is fused at its N-terminus to the C-terminus of one of the subunits of the Fc domain,
(c) the first complementing domain is fused at its N-terminus to the C-terminus of the first part of the effector domain; and
the second binding molecule comprises (i) a second and optionally a fourth antigen binding domain, (ii) an Fc domain composed of a first and a second subunit, (iii) a second part of an effector domain, and (iv) a second complementing domain,
wherein
(a) the second and the fourth (where present) antigen binding domain is fused at its C-terminus to the N-terminus of one of the subunits of the Fc domain,
(b) the second part of the effector domain is fused at its N-terminus to the C-terminus of one of the subunits of the Fc domain,
(c) the second complementing domain is fused at its N-terminus to the C-terminus of the second part of the effector domain.

### Claim 42 (depends on 1)

The pair of binding molecules of claim 1, wherein the first part of the effector domain and the first complementing domain, and/or the second part of the effector domain and the second complementing domain are fused via a peptide linker.

### Claim 43

(canceled)

### Claim 44 (depends on 1)

A binding molecule that forms part of the pair of binding molecules of claim 1.

### Claim 45 (depends on 1)

An isolated polynucleotide encoding the pair of binding molecules of claim 1.

### Claim 46 (depends on 45)

A host cell comprising the isolated polynucleotide of claim 45.

### Claim 47 (depends on 46)

A method of producing a pair of binding molecules, comprising the steps of (a) culturing the host cell of claim 46 under conditions suitable for the expression of the pair of binding molecules and optionally (b) recovering the pair of binding molecules.

### Claim 48 (depends on 1)

A pharmaceutical composition comprising the pair of binding molecules of claim 1 and a pharmaceutically acceptable carrier.

### Claim at position 29

-54. (canceled)

### Claim 55 (depends on 1)

A method of treating cancer in an individual, comprising administering to said individual an effective amount of the pair of binding molecules of claim 1.

### Claim 56

(canceled)

### Claim 57 (depends on 1)

A kit for the treatment of cancer, comprising (i) a container comprising a pharmaceutical composition, wherein the pharmaceutical composition comprises the pair of binding molecules of claim 1 and a pharmaceutically acceptable carrier, and (ii) a label or package insert containing instructions for using the pharmaceutical composition in the treatment of the disease.

### Claim 58 (depends on 1)

A kit for the treatment of cancer, comprising (i) a first container comprising a first pharmaceutical composition, wherein the first pharmaceutical composition comprises the first binding molecule of the pair of binding molecules of claim 1 and a pharmaceutically acceptable carrier, (ii) a second container comprising a second pharmaceutical composition, wherein the second pharmaceutical composition comprises the second binding molecule of the pair of binding molecules of claim 1 and a pharmaceutically acceptable carrier, and optionally (iii) a label or package insert containing instructions for using the first and the second pharmaceutical composition in combination in the treatment of the disease.

### Claim 59

(canceled)

### Claim 60 (depends on 1)

A method for forming a functional effector domain, comprising contacting the pair of binding molecules of claim 1 with a cell expressing the target antigens of the first and the second antigen binding domains, under conditions allowing binding of the first and the second antigen binding domain to their target antigens on the surface of the cell.

### Claim 61

(canceled)
